{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:49:01Z","timestamp":1792511341757,"version":"4.5.0"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Skin toxic effects are a common early adverse event of enfortumab vedotin plus pembrolizumab (EVP) therapy, but its association with clinical outcomes in patients receiving first-line therapy remains uncertain.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association between treatment-emergent skin toxic effects and clinical outcomes among patients receiving first-line EVP.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study was performed at the University of Texas MD Anderson Cancer Center among adults with locally advanced or metastatic urothelial carcinoma receiving first-line EVP therapy between March 3, 2022, and July 31, 2025. Skin toxic effects were used as a time-dependent exposure in Cox proportional hazards regression to account for immortal-time bias. Prespecified sequential adjustment models and 30-day landmark analyses were performed to assess the robustness of the findings.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Treatment-emergent skin toxic effects (rash or pruritus) were identified from medical records.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary outcome was overall survival (OS). Secondary outcomes included progression-free survival and objective response rate (ORR). OS and PFS were measured from EVP therapy initiation to the respective event or last follow-up. ORR was evaluated among patients with a response assessment after the 30-day landmark, according to skin toxic effects status within the first 30 days.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 185 patients (median age, 73 [IQR, 67-79] years; 140 [75.7%] male), skin toxic effects occurred in 98 (53.0%) at a median of 14 (IQR, 7-28) days after EVP therapy initiation. Skin toxic effects of grade 3 or higher occurred in 10 patients (5.4%). Skin toxic effects resulted in EV dose reduction in 31 patients (16.8%), treatment interruption in 20 (10.8%), and treatment discontinuation in 9 (4.9%). At a median follow-up of 17.7 (IQR, 11.3-24.2) months, Simon-Makuch curves demonstrated longer OS and PFS among all patients and longer OS among patients with visceral metastases in the skin toxic effects stratum than in the no toxicity stratum. In adjusted time-dependent Cox proportional hazards regression, skin toxic effects were associated with longer OS (hazard ratio, 0.34 [95% CI, 0.20-0.57]). The association remained consistent across sequential adjustment models and prespecified 30-day landmark analyses. In the 30-day landmark analyses, associations with PFS and ORR remained directionally favorable but were attenuated after multivariable adjustment.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of 185 patients with locally advanced or metastatic urothelial carcinoma receiving first-line EVP therapy, treatment-emergent skin toxic effects were associated with longer OS. These findings support further prospective validation of skin toxic effects as an early clinical marker of treatment benefit and investigation of the biological mechanisms underlying this association.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.39517","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:30:17Z","timestamp":1792510217000},"page":"e2639517","source":"Crossref","is-referenced-by-count":0,"title":["Skin Toxic Effects and Survival With Enfortumab Vedotin\u2013Pembrolizumab in Advanced Urothelial Carcinoma"],"prefix":"10.1001","volume":"9","author":[{"given":"Zachariah","family":"Thomas","sequence":"first","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy Y.","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Speck","sequence":"additional","affiliation":[{"name":"Internal Medical Residency Program, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Crupi","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Jad","family":"Moussa","sequence":"additional","affiliation":[{"name":"Internal Medical Residency Program, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Joseph","sequence":"additional","affiliation":[{"name":"Department of Dermatology, UT Health Houston, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Stender","sequence":"additional","affiliation":[{"name":"Department of Dermatology, UT Health Houston, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Glover","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Johns","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amishi Y.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Goswami","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Siefker-Radtke","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anishia-Rawther","family":"Karedath","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheeba P.","family":"Varughese","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Comron","family":"Hassanzadeh","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K.","family":"Bree","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Pacha","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Curry","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex D.","family":"Sherry","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alhalabi","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"issue":"1","key":"zoi261073r1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lungcan.2012.06.009","article-title":"Relationship between skin rash and outcome in non\u2013small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.","volume":"78","author":"Petrelli","year":"2012","journal-title":"Lung Cancer"},{"issue":"5","key":"zoi261073r2","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.jgo.2021.02.002","article-title":"Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer.","volume":"12","author":"Johns","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"10","key":"zoi261073r3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer.","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi261073r4","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma.","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi261073r6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"3","key":"zoi261073r7","doi-asserted-by":"publisher","first-page":"271.e1","DOI":"10.1016\/j.clgc.2020.08.003","article-title":"Causal diagram techniques for urologic oncology research.","volume":"19","author":"Shapiro","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"zoi261073r9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.euo.2020.12.006","article-title":"A new prognostic model in patients with advanced urothelial carcinoma treated with first-line immune checkpoint inhibitors.","volume":"4","author":"Khaki","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"zoi261073r10","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi261073r11","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.","volume":"17","author":"Bajorin","year":"1999","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi261073r12","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1097\/JU.0000000000001199","article-title":"Five-factor prognostic model for survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-L1 inhibitors.","volume":"204","author":"Sonpavde","year":"2020","journal-title":"J Urol"},{"issue":"2","key":"zoi261073r13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"3","key":"zoi261073r14","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the Nectin-4\u2013directed antibody-drug conjugate enfortumab vedotin.","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"issue":"6","key":"zoi261073r15","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.jaad.2020.11.067","article-title":"Clinicopathologic characterization of enfortumab vedotin\u2013associated cutaneous toxicity in patients with urothelial carcinoma.","volume":"85","author":"Hirotsu","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"zoi261073r16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"zoi261073r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115427","article-title":"Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin.","volume":"222","author":"Belka\u00efd","year":"2025","journal-title":"Eur J Cancer"},{"key":"zoi261073r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2026.101255","article-title":"Neutrophil-to-lymphocyte ratio and performance status are associated with increased risk of skin toxicity in patients receiving enfortumab vedotin with or without pembrolizumab for metastatic urothelial carcinoma.","volume":"48","author":"Hayashi","year":"2026","journal-title":"Cancer Treat Res Commun"},{"key":"zoi261073r5","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). November 27, 2017. Accessed April 13, 2023. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf"},{"key":"zoi261073r8","unstructured":"DAGitty, version 3.1. Accessed November 7, 2025. https:\/\/dagitty.net\/dags.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2855497\/thomas_2026_oi_261073_1791898666.42509.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:30:18Z","timestamp":1792510218000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2855497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.39517","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]}}}